This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - C3.ai ( NYSE:AI ) , Aspen Aerogels ( NYSE:ASPN )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Jefferies analyst James Heaney downgraded The Trade Desk, Inc.
MaxCyte ( MXCT ) Q2 Revenue Drops 18%
MaxCyte ( NASDAQ:MXCT ) , a cell engineering and biotechnology platform provider, reported its second quarter 2025 results on August 6, 2025. The most important news was an 18% year-over-year decline in total revenue ( GAAP ) and a downward revision of its full-year outlook.
MaxCyte, Inc. ( MXCT ) Reports Q2 Loss, Misses Revenue Estimates
MaxCyte (MXCT) delivered earnings and revenue surprises of -20.00% and -14.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
MaxCyte Signs Platform License Agreement with Adicet Bio
MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support development of Adicet's gamma delta T cell therapy gene edited programs ...
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
MaxCyte's Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca's TCR-T cell therapies MaxCyte's Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca's TCR-T cell therapies ...
Interim Management Statement Q3 2025
28 July ...
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
ROCKVILLE, Md., July 09, 2025 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., ( NASDAQ: MXCT ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it ...
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten ...
MaxCyte, Inc. ( MXCT ) Reports Q1 Loss, Tops Revenue Estimates
MaxCyte (MXCT) delivered earnings and revenue surprises of 0% and 7.11%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
ROCKVILLE, Md., April 10, 2025 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., ( NASDAQ: MXCT. LSE: MXCT ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced ...
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 - MaxCyte ( NASDAQ:MXCT )
ROCKVILLE, Md., April 10, 2025 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., MXCTMXCT ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will ...
Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte ( MXCT )
MaxCyte (MXCT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -30.2% in 4 Weeks, Here's Why MaxCyte ( MXCT ) Looks Ripe for a Turnaround
MaxCyte (MXCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
MaxCyte ( MXCT ) Upgraded to Buy: Here's What You Should Know
MaxCyte (MXCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Lazard ( NYSE:LAZ ) , Amylyx Pharmaceuticals ( NASDAQ:AMLX )
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Wednesday. Shares of Hello Group Inc. MOMO fell sharply during pre-market trading after reporting weak quarterly results. Hello Group posted fourth-quarter adjusted EPADS of 18 cents missing estimates ...
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance
ROCKVILLE, MD, March 11, 2025 - MaxCyte, Inc., ( NASDAQ: MXCT. LSE: MXCT ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its fourth quarter ...
Atara Biotherapeutics ( ATRA ) Reports Q4 Loss, Tops Revenue Estimates
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 68.85% and 150.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Alector ( ALEC ) Reports Q4 Loss, Tops Revenue Estimates
Alector (ALEC) delivered earnings and revenue surprises of 96.88% and 220.64%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs - MaxCyte ( NASDAQ:MXCT )
ROCKVILLE, Md., Feb. 12, 2025 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., MXCTMXCT ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced they are ...
MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference
ROCKVILLE, Md., Feb. 07, 2025 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., ( NASDAQ: MXCT. LSE: MXCT ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced ...
MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference - MaxCyte ( NASDAQ:MXCT )
ROCKVILLE, Md., Feb. 07, 2025 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., MXCTMXCT ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will ...
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments
ROCKVILLE, Md., Jan. 30, 2025 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., ( Nasdaq: MXCT. LSE: MXCT ) , a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of next-generation cell therapeutics announced today the acquisition of ...
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments - MaxCyte ( NASDAQ:MXCT )
ROCKVILLE, Md., Jan. 30, 2025 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., MXCTMXCT ) , a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of next-generation cell therapeutics announced today the acquisition of SeQure Dx, a market ...
All You Need to Know About MaxCyte ( MXCT ) Rating Upgrade to Strong Buy
MaxCyte (MXCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
ROCKVILLE, Md., Jan. 13, 2025 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., ( Nasdaq: MXCT. LSE: MXCT ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today provided a ...
MaxCyte Announces Retirement of Board Member Art Mandell
ROCKVILLE, Md., Dec. 22, 2024 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., ( Nasdaq: MXCT. LSE: MXCT ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced ...
MaxCyte Announces Retirement of Board Member Art Mandell - MaxCyte ( NASDAQ:MXCT )
ROCKVILLE, Md., Dec. 22, 2024 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., MXCTMXCT ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that Art Mandell ...
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance
ROCKVILLE, Md., Dec. 08, 2024 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., ( Nasdaq: MXCT. LSE: MXCT ) , a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced ...
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance - MaxCyte ( NASDAQ:MXCT )
ROCKVILLE, Md., Dec. 08, 2024 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., MXCTMXCT ) , a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the completion of ...
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
Since 1999, MaxCyte's non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects Since 1999, MaxCyte's non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects ...
MaxCyte, Inc. ( MXCT ) Reports Q3 Loss, Tops Revenue Estimates
MaxCyte (MXCT) delivered earnings and revenue surprises of 15.38% and 8.85%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
MaxCyte to Participate in Two Upcoming Investor Conferences - MaxCyte ( NASDAQ:MXCT )
ROCKVILLE, Md., Oct. 31, 2024 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., MXCTMXCT ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced Company ...
MaxCyte ( MXCT ) Upgraded to Strong Buy: What Does It Mean for the Stock?
MaxCyte (MXCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
MaxCyte Appoints Cynthia Collins to its Board of Directors - DermTech ( OTC:DMTKQ ) , Certara ( NASDAQ:CERT )
ROCKVILLE, Md., Oct. 15, 2024 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., MXCTMXCT ) ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative ...
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
ROCKVILLE, Md., Oct. 11, 2024 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., ( NASDAQ: MXCT. LSE: MXCT ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative ...
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
ROCKVILLE, Md., Oct. 10, 2024 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., ( Nasdaq: MXCT. LSE: MXCT ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and ...
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer - MaxCyte ( NASDAQ:MXCT )
ROCKVILLE, Md., Oct. 10, 2024 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., MXCTMXCT ) ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative ...
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
Kamau to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support its homology-directed repair ( HDR ) novel gene correction technology Kamau to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support its homology-directed repair ( HDR ) novel gene ...
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases - MaxCyte ( NASDAQ:MXCT )
ROCKVILLE, Md. and SOUTH SAN FRANCISCO, Calif., Sept. 15, 2024 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., MXCTMXCT ) ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based ...
MaxCyte, Inc. ( MXCT ) Reports Q2 Loss, Tops Revenue Estimates
MaxCyte (MXCT) delivered earnings and revenue surprises of 35.71% and 27.18%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Vir Biotechnology, Inc. ( VIR ) Reports Q2 Loss, Lags Revenue Estimates
Vir Biotechnology (VIR) delivered earnings and revenue surprises of -9.68% and 71.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
Company announces appointments of Dr. Claudio Dansky Ullmann as CMO and Ms. Karen Andreas as VP, Clinical Operations ...
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations - Context Therapeutics ( NASDAQ:CNTX )
Company announces appointments of Dr. Claudio Dansky Ullmann as CMO and Ms. Karen Andreas as VP, Clinical Operations Appointments support the development of the Company's two clinical-stage T cell engaging assets to treat solid tumors
MaxCyte ( MXCT ) is on the Move, Here's Why the Trend Could be Sustainable
MaxCyte (MXCT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Does MaxCyte ( MXCT ) Have the Potential to Rally 85% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 85% in MaxCyte (MXCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Recent Price Trend in MaxCyte ( MXCT ) is Your Friend, Here's Why
MaxCyte (MXCT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
ROCKVILLE, Md., May 29, 2024 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., ( NASDAQ: MXCT. LSE: MXCT ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and ...
MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference - MaxCyte ( NASDAQ:MXCT )
ROCKVILLE, Md., May 29, 2024 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., MXCTMXCT ) ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative ...
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
Legend Biotech obtains license to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support its non-viral engineered pipeline portfolio across a variety of cell types including T cells, Gamma-Delta T cells and NK Cells.
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday - Louisiana-Pacific ( NYSE:LPX )
U.S. stocks were mixed, with the Dow Jones gaining around 70 points on Wednesday. Shares of Louisiana-Pacific Corporation LPX rose sharply during Wednesday's session following better-than-expected first-quarter financial results.
